trial · primary record
Nivolumab
Hepato Cellular Carcinoma (HCC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2028-10-02 |
| Primary endpoint | Feasibility of single-dose neoadjuvant Nivolumab for resectable HCC |
| Registry ID | NCT07902258 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:58.220Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07902258
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.